Back

PCSK9 inhibitors are ready for daily life clincial use -Discussion PRO/CONTRA.

29 August 2016 (11:55 - 12:15)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors: ready to embrace? Drug therapy ESC Premium Access ESC Congress 2016

4 More presentations in this session

Presentation thumbnail
PCSK9 inhibitors: ready to embrace? - Positioning of the topic
Professor M. Sabatine (Boston, US)
Slides Video
Presentation thumbnail
PCSK9 inhibitors are ready for daily life clincial use - PRO
Professor E. Navarese (Sassari, IT)
Slides Video
Presentation thumbnail
PCSK9 inhibitors are ready for daily life clincial use - CON
Professor T. Pedersen (Oslo, NO)
Slides Video
Presentation thumbnail
PCSK9 inhibitors: ready to embrace? Conclusion.
Professor H. Drexel (Feldkirch, AT)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibitors: ready to embrace?

The Event

Event poster

ESC Congress 2016

29 August 2016 11:55 CET
You may be interested in
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes
1 September 2025
thumbnail
Congress Presentation
Present and the future of PCSK9 inhibition in cardiovascular prevention: from antibodies to gene editing - discussion
30 August 2026
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021
thumbnail
Congress Presentation
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources